LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair

• DOI: 10.1002/ctm2.341
• Publication Date: 2021-02-26T11:04:40Z
• Authors: Lifeng Chen; Jing Hou; Xiangyu Zeng; Qiang Guo; Min Deng; Jake A Kloeber; Xinyi Tu; Fei Zhao; Zheming Wu; Jinzhou Huang; Kuntian Luo; Wootae Kim; Zhenkun Lou
• Keywords: Ovarian Neoplasms; 0301 basic medicine; Medicine (General); Mice, Nude; Recombinational DNA Repair; Antineoplastic Agents; Drug Synergism; Poly(ADP-ribose) Polymerase Inhibitors; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; LRRK2 inhibitor; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; PARP inhibitor; R5-920; Cell Line, Tumor; HR; Rad51; Animals; Humans; DNA Breaks, Double-Stranded; Female; Research Articles

AbstractPARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR‐ deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore, there is a great clinical interest in exploring new therapies that induce HR deficiency (HRD), thereby sensitizing cancer cells to PARP inhibitors. Here, we found that GSK2578215A, a high‐selective and effective leucine‐rich repeat kinase 2 (LRRK2) inhibitor, or LRRK2 depletion suppresses HR preventing the recruitment of RAD51 to DNA damage sites through disruption of the interaction of RAD51 and BRCA2. Moreover, LRRK2 inhibition or depletion increases the susceptibility of ovarian cancer cells to Olaparib in vitro and in vivo. In clinical specimens, LRRK2 high expression is high related with advanced clinical characteristics and poor survival of ovarian cancer patients. All these findings indicate ovarian cancers expressing high levels of LRRK2 are more resistant to treatment potentially through promoting HR. Furthermore, combination treatment with an LRRK2 and PARP inhibitor may be a novel strategy to improve the effectiveness of LRRK2 expression ovarian cancers.